LIVIVO - Suchergebnisse -

Suchergebnis

Treffer 1 - 10 von insgesamt 10

Suchoptionen

Artikel ; Online: Differential Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Profiles After Allergic Reactions to Messenger RNA Coronavirus Disease 2019 Vaccine.

Maron, Jenny S / Conroy, Michelle / Naranbai, Vivek / Samarakoon, Upeka / Motazedi, Tina / Farmer, Jocelyn R / Freeman, Esther / Banerji, Aleena / Bartsch, Yannic C / Gregory, David J / Poznansky, Mark C / Alter, Galit / Blumenthal, Kimberly G

The Journal of infectious diseases

2022 Band 226, Heft 7, Seite(n) 1231–1236

Abstract: Allergic symptoms after messenger RNA (mRNA) coronavirus disease 2019 (COVID-19) vaccines occur in up to 2% of recipients. Compared to nonallergic controls (n = 18), individuals with immediate allergic reactions to mRNA COVID-19 vaccines (n = 8) mounted ... ...

Abstract	Allergic symptoms after messenger RNA (mRNA) coronavirus disease 2019 (COVID-19) vaccines occur in up to 2% of recipients. Compared to nonallergic controls (n = 18), individuals with immediate allergic reactions to mRNA COVID-19 vaccines (n = 8) mounted lower immunoglobulin G1 (IgG1) to multiple antigenic targets in severe acute respiratory syndrome coronavirus 2 spike following vaccination, with significantly lower IgG1 to full-length spike (P = .04). Individuals with immediate allergic reactions to mRNA COVID-19 vaccines bound Fcγ receptors similarly to nonallergic controls. Although there was a trend toward an overall reduction in opsonophagocytic function in individuals with immediate allergic reactions compared to nonallergic controls, allergic patients produced functional antibodies exhibiting a high ratio of opsonophagocytic function to IgG1 titer.
Mesh-Begriff(e)	2019-nCoV Vaccine mRNA-1273 ; COVID-19/prevention & control ; COVID-19 Vaccines/adverse effects ; Humans ; Hypersensitivity ; Immunity, Humoral ; Immunoglobulin G ; RNA, Messenger ; SARS-CoV-2 ; Vaccination
Chemische Substanzen	COVID-19 Vaccines ; Immunoglobulin G ; RNA, Messenger ; 2019-nCoV Vaccine mRNA-1273 (EPK39PL4R4)
Sprache	Englisch
Erscheinungsdatum	2022-03-22
Erscheinungsland	United States
Dokumenttyp	Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, N.I.H., Extramural
ZDB-ID	3019-3
ISSN	1537-6613 ; 0022-1899
ISSN (online)	1537-6613
ISSN	0022-1899
DOI	10.1093/infdis/jiac107
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Volltext online

Zugriff für angemeldete ZB MED Nutzerinnen und Nutzer

Zusatzmaterialien

Verfügbar in ZB MED Köln/Königswinter

Uh II Zs.50: Hefte anzeigen			Standort: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 445: Hefte anzeigen

Über subito bestellen

Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

Details ▾

Artikel ; Online: Anamnestic humoral correlates of immunity across SARS-CoV-2 variants of concern.

mBio

2023 Band 14, Heft 4, Seite(n) e0090223

Abstract: While immune correlates against SARS-CoV-2 are typically defined at peak immunogenicity following vaccination, immunologic responses that expand selectively during the anamnestic response following infection can provide mechanistic and detailed insights ... ...

Abstract	While immune correlates against SARS-CoV-2 are typically defined at peak immunogenicity following vaccination, immunologic responses that expand selectively during the anamnestic response following infection can provide mechanistic and detailed insights into the immune mechanisms of protection. Moreover, whether anamnestic correlates are conserved across variants of concern (VOC), including the Delta and more distant Omicron VOC, remains unclear. To define the anamnestic correlates of immunity, across VOCs, we deeply profiled the humoral immune response in individuals infected with sequence-confirmed Delta or Omicron VOC after completing the vaccination series. While limited acute N-terminal domain and receptor-binding domain (RBD)-specific immune expansion was observed following breakthrough infection, a significant immunodominant expansion of opsonophagocytic Spike-specific antibody responses focused largely on the conserved S2-domain of SARS-CoV-2 was observed. This S2-specific functional humoral response continued to evolve over 2-3 weeks following Delta or Omicron breakthrough, targeting multiple VOCs and common coronaviruses. Strong responses were observed on the fusion peptide (FP) region and the heptad repeat 1 (HR1) region adjacent to the RBD. Notably, the FP is highly conserved across SARS-related coronaviruses and even non-SARS-related betacoronavirus. Taken together, our results point to a critical role of highly conserved, functional S2-specific responses in the anamnestic antibody response to SARS-CoV-2 infection across VOCs. These humoral responses linked to virus clearance can guide next-generation vaccine-boosting approaches to confer broad protection against future SARS-related coronaviruses. IMPORTANCE The Spike protein of SARS-CoV-2 is the primary target of antibody-based recognition. Selective pressures, be it the adaption to human-to-human transmission or evasion of previously acquired immunity, have spurred the emergence of variants of the virus such as the Delta and Omicron lineages. Therefore, understanding how antibody responses are expanded in breakthrough cases of previously vaccinated individuals can provide insights into key correlates of protection against current and future variants. Here, we show that vaccinated individuals who had documented COVID-19 breakthrough showed anamnestic antibody expansions targeting the conserved S2 subdomain of Spike, particularly within the fusion peptide region. These S2-directed antibodies were highly leveraged for non-neutralizing, phagocytic functions and were similarly expanded independent of the variant. We propose that through deep profiling of anamnestic antibody responses in breakthrough cases, we can identify antigen targets susceptible to novel monoclonal antibody therapy or vaccination-boosting strategies.
Mesh-Begriff(e)	Humans ; COVID-19 ; SARS-CoV-2/genetics ; Antibodies ; Antibodies, Viral ; Antibodies, Neutralizing
Chemische Substanzen	Antibodies ; Antibodies, Viral ; Antibodies, Neutralizing
Sprache	Englisch
Erscheinungsdatum	2023-08-03
Erscheinungsland	United States
Dokumenttyp	Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, N.I.H., Extramural
ZDB-ID	2557172-2
ISSN	2150-7511 ; 2161-2129
ISSN (online)	2150-7511
ISSN	2161-2129
DOI	10.1128/mbio.00902-23
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Über subito bestellen

Details ▾
- Kostenpflichtig bestellen

Artikel ; Online: Fc-mediated pan-sarbecovirus protection after alphavirus vector vaccination.

Adams, Lily E / Leist, Sarah R / Dinnon, Kenneth H / West, Ande / Gully, Kendra L / Anderson, Elizabeth J / Loome, Jennifer F / Madden, Emily A / Powers, John M / Schäfer, Alexandra / Sarkar, Sanjay / Castillo, Izabella N / Maron, Jenny S / McNamara, Ryan P / Bertera, Harry L / Zweigert, Mark R / Higgins, Jaclyn S / Hampton, Brea K / Premkumar, Lakshmanane /

Alter, Galit / Montgomery, Stephanie A / Baxter, Victoria K / Heise, Mark T / Baric, Ralph S

Cell reports

2023 Band 42, Heft 4, Seite(n) 112326

Abstract: Group 2B β-coronaviruses (sarbecoviruses) have caused regional and global epidemics in modern history. Here, we evaluate the mechanisms of cross-sarbecovirus protective immunity, currently less clear yet important for pan-sarbecovirus vaccine development, ...

Abstract	Group 2B β-coronaviruses (sarbecoviruses) have caused regional and global epidemics in modern history. Here, we evaluate the mechanisms of cross-sarbecovirus protective immunity, currently less clear yet important for pan-sarbecovirus vaccine development, using a panel of alphavirus-vectored vaccines covering bat to human strains. While vaccination does not prevent virus replication, it protects against lethal heterologous disease outcomes in both severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and clade 2 bat sarbecovirus challenge models. The spike vaccines tested primarily elicit a highly S1-specific homologous neutralizing antibody response with no detectable cross-virus neutralization. Rather, non-neutralizing antibody functions, mechanistically linked to FcgR4 and spike S2, mediate cross-protection in wild-type mice. Protection is lost in FcR knockout mice, further supporting a model for non-neutralizing, protective antibodies. These data highlight the importance of FcR-mediated cross-protective immune responses in universal pan-sarbecovirus vaccine designs.
Mesh-Begriff(e)	Humans ; Animals ; Mice ; Viral Vaccines ; Antibodies, Viral ; Alphavirus ; Severe acute respiratory syndrome-related coronavirus ; Chiroptera ; SARS-CoV-2 ; COVID-19/prevention & control ; Antibodies, Neutralizing ; Vaccination
Chemische Substanzen	Viral Vaccines ; Antibodies, Viral ; Antibodies, Neutralizing
Sprache	Englisch
Erscheinungsdatum	2023-03-30
Erscheinungsland	United States
Dokumenttyp	Journal Article ; Research Support, U.S. Gov't, Non-P.H.S. ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
ZDB-ID	2649101-1
ISSN	2211-1247 ; 2211-1247
ISSN (online)	2211-1247
ISSN	2211-1247
DOI	10.1016/j.celrep.2023.112326
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Über subito bestellen

Details ▾
- Kostenpflichtig bestellen

Artikel ; Online: Anamnestic Humoral Correlates of Immunity Across SARS-CoV-2 Variants of Concern

McNamara, Ryan / Maron, Jenny S / Bertera, Harry L / Boucau, Julie / Roy, Vicky / Barczak, Amy K. / The Positives Study Staff / Franko, Nicholas / Li, Jonathan Z / McLellan, Jason S / Siedner, Mark / Lemieux, Jacob E / Chu, Helen / Alter, Galit

bioRxiv

Abstract	While immune correlates against SARS-CoV-2 are typically defined at peak immunogenicity following vaccination, immunologic responses that expand selectively during the anamnestic response following infection can provide mechanistic and detailed insights into the immune mechanisms of protection. Moreover, whether anamnestic correlates are conserved across VoCs, including the Delta and more distant Omicron variant of concern (VoC), remains unclear. To define the anamnestic correlates of immunity, across VOCs, we deeply profiled the humoral immune response in individuals recently infected with either the Delta or Omicron VoC. While limited acute N-terminal domain and RBD-specific immune expansion was observed following breakthrough, a significant immunodominant expansion of opsinophagocytic Spike-specific antibody responses focused largely on the conserved S2-domain of SARS-CoV-2 was observed 1 week after breakthrough infection. This S2-specific functional humoral response continued to evolve over 2-3 weeks following both Delta and Omicron breakthrough infection, targeting multiple VoCs and common coronaviruses. These responses were focused largely on the fusion peptide 2 and heptad repeat 1, both associated with enhanced rates of viral clearance. Taken together, our results point to a critical role of highly conserved, functional S2-specific responses in the control of SARS-CoV-2 infection, across VOCs, and thus humoral response linked to virus attenuation can guide next-generation generation vaccine boosting approaches to confer broad protection against future SARS-CoV-2 VoCs.
Schlagwörter	covid19
Sprache	Englisch
Erscheinungsdatum	2022-06-21
Verlag	Cold Spring Harbor Laboratory
Dokumenttyp	Artikel ; Online
DOI	10.1101/2022.06.19.496718
Datenquelle	COVID19

Volltext online

Fernleihe an ZB MED

Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

Artikel: Fc mediated pan-sarbecovirus protection after alphavirus vector vaccination.

Alter, Galit / Montgomery, Stephanie A / Baxter, Victoria K / Heise, Mark T / Baric, Ralph S

bioRxiv : the preprint server for biology

2022

Abstract: Two group 2B β-coronaviruses (sarbecoviruses) have caused regional and global epidemics in modern history. The mechanisms of cross protection driven by the sarbecovirus spike, a dominant immunogen, are less clear yet critically important for pan- ... ...

Abstract	Two group 2B β-coronaviruses (sarbecoviruses) have caused regional and global epidemics in modern history. The mechanisms of cross protection driven by the sarbecovirus spike, a dominant immunogen, are less clear yet critically important for pan-sarbecovirus vaccine development. We evaluated the mechanisms of cross-sarbecovirus protective immunity using a panel of alphavirus-vectored vaccines covering bat to human strains. While vaccination did not prevent virus replication, it protected against lethal heterologous disease outcomes in both SARS-CoV-2 and clade 2 bat sarbecovirus HKU3-SRBD challenge models. The spike vaccines tested primarily elicited a highly S1-specific homologous neutralizing antibody response with no detectable cross-virus neutralization. We found non-neutralizing antibody functions that mediated cross protection in wild-type mice were mechanistically linked to FcgR4 and spike S2-binding antibodies. Protection was lost in FcR knockout mice, further supporting a model for non-neutralizing, protective antibodies. These data highlight the importance of FcR-mediated cross-protective immune responses in universal pan-sarbecovirus vaccine designs.
Sprache	Englisch
Erscheinungsdatum	2022-11-28
Erscheinungsland	United States
Dokumenttyp	Preprint
DOI	10.1101/2022.11.28.518175
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Fernleihe an ZB MED

Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

Details ▾

Artikel ; Online: Humoral and cellular immunogenicity of SARS-CoV-2 vaccines in chronic lymphocytic leukemia: a prospective cohort study.

Haydu, J Erika / Maron, Jenny S / Redd, Robert A / Gallagher, Kathleen M E / Fischinger, Stephanie / Barnes, Jeffrey A / Hochberg, Ephraim P / Johnson, P Connor / Takvorian, R W / Katsis, Katelin / Portman, Daneal / Ruiters, Jade / Sechio, Sidney / Devlin, Mary / Regan, Connor / Blumenthal, Kimberly G / Banerji, Aleena / Judd, Allen D / Scorsune, Krista J /

McGree, Brianne M / Sherburne, Maryanne M / Lynch, Julia M / Weitzman, James I / Lei, Matthew / Kotton, Camille N / Dighe, Anand S / Maus, Marcela V / Alter, Galit / Abramson, Jeremy S / Soumerai, Jacob D

Blood advances

2022 Band 6, Heft 6, Seite(n) 1671–1683

Abstract: Chronic lymphocytic leukemia (CLL), the most common leukemia worldwide, is associated with increased COVID-19 mortality. Previous studies suggest only a portion of vaccinated CLL patients develop severe acute respiratory syndrome coronavirus 2 (SARS-CoV- ... ...

Abstract	Chronic lymphocytic leukemia (CLL), the most common leukemia worldwide, is associated with increased COVID-19 mortality. Previous studies suggest only a portion of vaccinated CLL patients develop severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike antibodies. Whether the elicited antibodies are functional and/or accompanied by functional T-cell responses is unknown. This prospective cohort study included patients with CLL who received SARS-CoV-2 and PCV13 vaccines (not concurrently). The primary cohort included adults with CLL off therapy. Coprimary outcomes were serologic response to SARS-CoV-2 (receptor binding domain [RBD] immunoassay) and PCV13 vaccines (23-serotype IgG assay). Characterization of SARS-CoV-2 antibodies and their functional activity and assessment of functional T-cell responses was performed. Sixty percent (18/30) of patients demonstrated serologic responses to SARS-CoV-2 vaccination, appearing more frequent among treatment-naïve patients (72%). Among treatment-naïve patients, an absolute lymphocyte count ≤24 000/µL was associated with serologic response (94% vs 14%; P < .001). On interferon-γ release assays, 80% (16/20) of patients had functional spike-specific T-cell responses, including 78% (7/9) with a negative RBD immunoassay, a group enriched for prior B-cell-depleting therapies. A bead-based multiplex immunoassay identified antibodies against wild-type and variant SARS-CoV-2 (α, β, γ, and δ) in all tested patients and confirmed Fc-receptor binding and effector functions of these antibodies. Of 11 patients with negative RBD immunoassay after vaccination, 6 (55%) responded to an additional mRNA-based vaccine dose. The PCV13 serologic response rate was 29% (8/28). Our data demonstrate that SARS-CoV-2 vaccination induces functional T-cell and antibody responses in patients with CLL and provides the framework for investigating the molecular mechanisms and clinical benefit of these responses. This trial was registered at www.clinicaltrials.gov as #NCT05007860.
Mesh-Begriff(e)	Adult ; Antibodies, Neutralizing ; COVID-19/prevention & control ; COVID-19 Vaccines ; Humans ; Immunogenicity, Vaccine ; Leukemia, Lymphocytic, Chronic, B-Cell/therapy ; Prospective Studies ; SARS-CoV-2
Chemische Substanzen	Antibodies, Neutralizing ; COVID-19 Vaccines
Sprache	Englisch
Erscheinungsdatum	2022-03-04
Erscheinungsland	United States
Dokumenttyp	Clinical Trial ; Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
ZDB-ID	2915908-8
ISSN	2473-9537 ; 2473-9529
ISSN (online)	2473-9537
ISSN	2473-9529
DOI	10.1182/bloodadvances.2021006627
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Verfügbar in ZB MED Köln/Königswinter

Zs.A 7153: Hefte anzeigen

Standort:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Über subito bestellen

Details ▾
- Im ZB MED-Bestand
- Kostenpflichtig bestellen

Artikel ; Online: Serological Markers of SARS-CoV-2 Reinfection.

Siddiqui, Sameed M / Bowman, Kathryn A / Zhu, Alex L / Fischinger, Stephanie / Beger, Samuel / Maron, Jenny S / Bartsch, Yannic C / Atyeo, Caroline / Gorman, Matthew J / Yanis, Ahmad / Hultquist, Judd F / Lorenzo-Redondo, Ramon / Ozer, Egon A / Simons, Lacy M / Talj, Rana / Rankin, Danielle A / Chapman, Lindsay / Meade, Kyle / Steinhart, Jordan /

Mullane, Sean / Siebert, Suzanne / Streeck, Hendrik / Sabeti, Pardis / Halasa, Natasha / Musk, Elon R / Barouch, Dan H / Menon, Anil S / Nilles, Eric J / Lauffenburger, Douglas A / Alter, Galit

mBio

2022 Band 13, Heft 1, Seite(n) e0214121

Abstract: As public health guidelines throughout the world have relaxed in response to vaccination campaigns against SARS-CoV-2, it is likely that SARS-CoV-2 will remain endemic, fueled by the rise of more infectious SARS-CoV-2 variants. Moreover, in the setting ... ...

Abstract	As public health guidelines throughout the world have relaxed in response to vaccination campaigns against SARS-CoV-2, it is likely that SARS-CoV-2 will remain endemic, fueled by the rise of more infectious SARS-CoV-2 variants. Moreover, in the setting of waning natural and vaccine immunity, reinfections have emerged across the globe, even among previously infected and vaccinated individuals. As such, the ability to detect reexposure to and reinfection by SARS-CoV-2 is a key component for global protection against this virus and, more importantly, against the potential emergence of vaccine escape mutations. Accordingly, there is a strong and continued need for the development and deployment of simple methods to detect emerging hot spots of reinfection to inform targeted pandemic response and containment, including targeted and specific deployment of vaccine booster campaigns. In this study, we identify simple, rapid immune biomarkers of reinfection in rhesus macaques, including IgG3 antibody levels against nucleocapsid and FcγR2A receptor binding activity of anti-RBD antibodies, that are recapitulated in human reinfection cases. As such, this cross-species analysis underscores the potential utility of simple antibody titers and function as price-effective and scalable markers of reinfection to provide increased resolution and resilience against new outbreaks.
Mesh-Begriff(e)	Animals ; Humans ; Reinfection ; Macaca mulatta ; SARS-CoV-2 ; COVID-19 ; Immunoglobulin G ; Antibodies, Viral ; Antibodies, Neutralizing
Chemische Substanzen	Immunoglobulin G ; Antibodies, Viral ; Antibodies, Neutralizing
Sprache	Englisch
Erscheinungsdatum	2022-01-25
Erscheinungsland	United States
Dokumenttyp	Journal Article ; Research Support, U.S. Gov't, P.H.S. ; Research Support, Non-U.S. Gov't ; Research Support, N.I.H., Extramural ; Research Support, U.S. Gov't, Non-P.H.S.
ZDB-ID	2557172-2
ISSN	2150-7511 ; 2161-2129
ISSN (online)	2150-7511
ISSN	2161-2129
DOI	10.1128/mbio.02141-21
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Über subito bestellen

Details ▾
- Kostenpflichtig bestellen

Artikel ; Online: A homologous or variant booster vaccine after Ad26.COV2.S immunization enhances SARS-CoV-2-specific immune responses in rhesus macaques.

He, Xuan / Aid, Malika / Chandrashekar, Abishek / Yu, Jingyou / McMahan, Katherine / Wegmann, Frank / Jacob-Dolan, Catherine / Maron, Jenny S / Atyeo, Caroline / Wan, Huahua / Sellers, Daniel / Liu, Jinyan / Lifton, Michelle / Gardner, Sarah / Bondzie, Esther A / Barrett, Julia / Ahmad, Kunza / Anioke, Tochi / Yalley-Ogunro, Jake /

Muench, Jeanne / Goode, Adrienne / Andersen, Hanne / Lewis, Mark G / Alter, Galit / Schuitemaker, Hanneke / Zahn, Roland / Barouch, Dan H

Science translational medicine

2022 Band 14, Heft 638, Seite(n) eabm4996

Abstract: Ad26.COV2.S has demonstrated durability and clinical efficacy against symptomatic COVID-19 in humans. In this study, we report the correlates of durability of humoral and cellular immune responses in 20 rhesus macaques immunized with single-shot Ad26 ... ...

Abstract	Ad26.COV2.S has demonstrated durability and clinical efficacy against symptomatic COVID-19 in humans. In this study, we report the correlates of durability of humoral and cellular immune responses in 20 rhesus macaques immunized with single-shot Ad26.COV2.S and the immunogenicity of a booster shot at 8 to 10 months after the initial immunization. Ad26.COV2.S elicited durable binding and neutralizing antibodies as well as memory B cells and long-lived bone marrow plasma cells. Innate immune responses and bone marrow plasma cell responses correlated with durable antibody responses. After Ad26.COV2.S boost immunization, binding and neutralizing antibody responses against multiple SARS-CoV-2 variants increased 31- to 69-fold and 23- to 43-fold, respectively, compared with preboost concentrations. Antigen-specific B cell and T cell responses also increased substantially after the boost immunization. Boosting with a modified Ad26.COV2.S.351 vaccine expressing the SARS-CoV-2 spike protein from the beta variant led to largely comparable responses with slightly higher beta- and omicron-specific humoral immune responses. These data demonstrate that a late boost with Ad26.COV2.S or Ad26.COV2.S.351 resulted in a marked increase in humoral and cellular immune responses that were highly cross-reactive across multiple SARS-CoV-2 variants in rhesus macaques.
Mesh-Begriff(e)	Ad26COVS1/immunology ; Animals ; Antibodies, Neutralizing ; Antibodies, Viral ; COVID-19/prevention & control ; Immunity, Humoral ; Immunization, Secondary ; Macaca mulatta ; SARS-CoV-2 ; Spike Glycoprotein, Coronavirus
Chemische Substanzen	Ad26COVS1 (JT2NS6183B) ; Antibodies, Neutralizing ; Antibodies, Viral ; Spike Glycoprotein, Coronavirus ; spike protein, SARS-CoV-2
Sprache	Englisch
Erscheinungsdatum	2022-03-30
Erscheinungsland	United States
Dokumenttyp	Journal Article
ZDB-ID	2518854-9
ISSN	1946-6242 ; 1946-6234
ISSN (online)	1946-6242
ISSN	1946-6234
DOI	10.1126/scitranslmed.abm4996
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Verfügbar in ZB MED Köln/Königswinter

Zs.A 6941: Hefte anzeigen

Standort:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Über subito bestellen

Details ▾
- Im ZB MED-Bestand
- Kostenpflichtig bestellen

Artikel ; Online: Fc mediated pan-sarbecovirus protection after alphavirus vector vaccination

Adams, Lily E. / Leist, Sarah R / Dinnon, Kenneth H / West, Ande / Gully, Kendra L / Anderson, Elizabeth / Loome, Jennifer F / Madden, Emily / Powers, John / Schaefer, Alexandra / Sarkar, Sanjay / Castillo, Izabella / Maron, Jenny / McNamara, Ryan P / Bertera, Harry L / Zweigart, Mark R / Higgins, Jaclyn S / Hampton, Brea K / Lakshmanane, Prem /

Alter, Galit / Montgomery, Stephanie / Baxter, Victoria / Heise, Mark T. / Baric, Ralph S.

bioRxiv

Abstract: Two group 2B beta-coronaviruses (sarbecoviruses) have caused regional and global epidemics in modern history. The mechanisms of cross protection driven by the sarbecovirus spike, a dominant immunogen, are less clear yet critically important for pan- ... ...

Abstract	Two group 2B beta-coronaviruses (sarbecoviruses) have caused regional and global epidemics in modern history. The mechanisms of cross protection driven by the sarbecovirus spike, a dominant immunogen, are less clear yet critically important for pan-sarbecovirus vaccine development. We evaluated the mechanisms of cross-sarbecovirus protective immunity using a panel of alphavirus-vectored vaccines covering bat to human strains. While vaccination did not prevent virus replication, it protected against lethal heterologous disease outcomes in both SARS-CoV-2 and clade 2 bat sarbecovirus HKU3-SRBD challenge models. The spike vaccines tested primarily elicited a highly S1-specific homologous neutralizing antibody response with no detectable cross-virus neutralization. We found non-neutralizing antibody functions that mediated cross protection in wild-type mice were mechanistically linked to FcgR4 and spike S2-binding antibodies. Protection was lost in FcR knockout mice, further supporting a model for non-neutralizing, protective antibodies. These data highlight the importance of FcR-mediated cross-protective immune responses in universal pan-sarbecovirus vaccine designs.
Schlagwörter	covid19
Sprache	Englisch
Erscheinungsdatum	2022-11-28
Verlag	Cold Spring Harbor Laboratory
Dokumenttyp	Artikel ; Online
DOI	10.1101/2022.11.28.518175
Datenquelle	COVID19

Volltext online

Fernleihe an ZB MED

Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

Artikel ; Online: Differential Kinetics of Immune Responses Elicited by Covid-19 Vaccines.

Collier, Ai-Ris Y / Yu, Jingyou / McMahan, Katherine / Liu, Jinyan / Chandrashekar, Abishek / Maron, Jenny S / Atyeo, Caroline / Martinez, David R / Ansel, Jessica L / Aguayo, Ricardo / Rowe, Marjorie / Jacob-Dolan, Catherine / Sellers, Daniel / Barrett, Julia / Ahmad, Kunza / Anioke, Tochi / VanWyk, Haley / Gardner, Sarah / Powers, Olivia /

Bondzie, Esther A / Wan, Huahua / Baric, Ralph S / Alter, Galit / Hacker, Michele R / Barouch, Dan H

The New England journal of medicine

2021 Band 385, Heft 21, Seite(n) 2010–2012

Mesh-Begriff(e)	2019-nCoV Vaccine mRNA-1273/pharmacokinetics ; Ad26COVS1/pharmacokinetics ; Antibodies, Neutralizing/blood ; Antibodies, Viral/blood ; BNT162 Vaccine/pharmacokinetics ; COVID-19 Vaccines/administration & dosage ; COVID-19 Vaccines/immunology ; COVID-19 Vaccines/pharmacokinetics ; Humans ; Immunogenicity, Vaccine/physiology ; T-Lymphocytes/physiology
Chemische Substanzen	Ad26COVS1 (JT2NS6183B) ; Antibodies, Neutralizing ; Antibodies, Viral ; COVID-19 Vaccines ; 2019-nCoV Vaccine mRNA-1273 (EPK39PL4R4) ; BNT162 Vaccine (N38TVC63NU)
Sprache	Englisch
Erscheinungsdatum	2021-10-15
Erscheinungsland	United States
Dokumenttyp	Letter ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
ZDB-ID	207154-x
ISSN	1533-4406 ; 0028-4793
ISSN (online)	1533-4406
ISSN	0028-4793
DOI	10.1056/NEJMc2115596
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Verfügbar in ZB MED Köln/Königswinter

Ua VI Zs.34: Hefte anzeigen

Standort:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Über subito bestellen

Details ▾
- Im ZB MED-Bestand
- Kostenpflichtig bestellen

Zum Seitenanfang

Ihre letzten Suchen

Volltext online

Zusatzmaterialien

Kategorien

Verfügbar in ZB MED Köln/Königswinter

Über subito bestellen

Zusatzmaterialien

Kategorien

Über subito bestellen

Zusatzmaterialien

Kategorien

Über subito bestellen

Volltext online

Kategorien

Fernleihe an ZB MED

Zusatzmaterialien

Kategorien

Fernleihe an ZB MED

Zusatzmaterialien

Kategorien

Verfügbar in ZB MED Köln/Königswinter

Über subito bestellen

Zusatzmaterialien

Kategorien

Über subito bestellen

Zusatzmaterialien

Kategorien

Verfügbar in ZB MED Köln/Königswinter

Über subito bestellen

Volltext online

Kategorien

Fernleihe an ZB MED

Zusatzmaterialien

Kategorien

Verfügbar in ZB MED Köln/Königswinter

Über subito bestellen